Fintech

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Globenewswire·March 24, 2026 at 12:37 PM

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

Worth raises $30M for SMB onboarding platform
PYMNTS
Spade Raises $40 Million for Transaction Data Analysis
PYMNTS
FTC Bans Air AI From Marketing Business Opportunities
PYMNTS
Braze Earnings Show AI Demand
PYMNTS

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Worth raises $30M for SMB onboarding platform

Spade Raises $40 Million for Transaction Data Analysis

FTC Bans Air AI From Marketing Business Opportunities

Braze Earnings Show AI Demand